Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracranial Atherosclerotic Disease Distribution Across Circle of Willis Segments: Insights from CREST-H.

AJNR. American journal of neuroradiology·2026
Same author

An International, Multi-Specialty Consensus Document on the Optimal Management of Patients with Internal Carotid Artery Occlusion.

Journal of vascular surgery·2026
Same author

Carotid Artery Disease: Then and Now.

Stroke (Hoboken, N.J.)·2026
Same author

Design Matters: Challenges and Remedies in CREST-2.

Stroke·2026
Same author

CREST-2: Early reflections on the primary results.

Seminars in vascular surgery·2026
Same author

Carotid artery stenting with open vs closed stent cell configurations in the CREST-2 Registry.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026
Same journal

Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association.

Stroke·2026
Same journal

Update on Rehabilitation After Stroke: Global Changes and the Continued Importance of Therapy Intensity, Dose, and Timing.

Stroke·2026
Same journal

ENTF Neuromodulation Yields Reduced Disability After Stroke: An Individual Participant-Level Data Meta-Analysis.

Stroke·2026
Same journal

Menopause and Its Implications for Stroke in Women.

Stroke·2026
Same journal

Physician Approaches to Determining Goals of Stroke Care for Patients Living With Disability or Dementia: Results from the SEED Mixed-Methods Study.

Stroke·2026
Same journal

Aspirin for Stroke Primary Prevention: A Step Toward Genetic-Driven Personalized Medicine.

Stroke·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Pharmacogenetics and stroke.

James F Meschia1

  • 1Mayo Clinic, Jacksonville, Fla 32224, USA. meschia.james@mayo.edu

Stroke
|September 19, 2009
PubMed
Summary
This summary is machine-generated.

Genetic variations impact how stroke patients respond to medications like clopidogrel and statins. More research is needed to use genetic testing for personalized drug selection and dosing in stroke prevention.

Related Experiment Videos

Last Updated: Jun 20, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Area of Science:

  • Pharmacogenomics
  • Neurology
  • Cardiovascular Medicine

Background:

  • Genetic variations influence drug metabolism, adverse events, and responses to common stroke medications.
  • Drugs like clopidogrel, statins, antihypertensives, and coumadin are frequently used in stroke patients.
  • The clinical application of genetic testing in stroke treatment is still evolving.

Purpose of the Study:

  • To review the impact of genetic variations on drug efficacy and safety in stroke patients.
  • To highlight the need for further validation of genetic testing in clinical practice.
  • To discuss the challenges in implementing pharmacogenomics for individualized stroke medicine.

Main Methods:

  • Literature review of studies on genetic variations and stroke pharmacotherapy.
  • Analysis of drug response data in relation to patient genotypes.
  • Synthesis of current evidence on clinical utility and implementation barriers.

Main Results:

  • Significant associations found between genetic profiles and patient responses to key stroke drugs.
  • Identified specific genetic markers affecting metabolism and efficacy of clopidogrel, statins, and anticoagulants.
  • Clinical utility of genetic testing requires further validation for widespread adoption.

Conclusions:

  • Genetic variations play a crucial role in tailoring pharmacotherapy for stroke prevention and treatment.
  • Translating pharmacogenomic insights into individualized medicine requires collaboration among stakeholders.
  • Further research and validation are essential for integrating genetic testing into routine clinical care for stroke patients.